The role of HER 2/neu in patients with metastatic breast cancer undergoing high-dose chemotherapy

M. Bewick, A. Chadderton, S. Glück

Research output: Contribution to journalArticle

Abstract

HER 2/neu is known to be overexpressed in approximately Vb of newly diagnosed breast cancers but has not been examined in the majority of breast cancers that recurred after initial treatment. It was therefore evaluated using two different techniques whether the HER 2/neu product in the plasma (measured by EIA technique) and overexpression of the HER 2/neu oncogene (detected by semiquantative differential PCR) can be used as a prognostic marker, as a too] for detecting minimal residual disease after chemotherapy and also as a marker for treatment outcome. Plasma and peripheral blood samples were analyzed prior to treatment, during chemotherapy and after high-dose chemotherapy. The breast cancer patients were stratified for bone marrow involvement. Our results show a correlation between the amount of HER 2/neu protein product detected in the peripheral blood, the overexpression of the HER 2/neu in the peripheral blood cell population and the involvement of the patient's bone marrow. The study is ongoing and correlation between treatment outcomes and survival of over 32 patients is evaluated.

Original languageEnglish
JournalExperimental Hematology
Volume24
Issue number9
StatePublished - Dec 1 1996
Externally publishedYes

Fingerprint

Breast Neoplasms
Drug Therapy
Bone Marrow
Residual Neoplasm
Oncogenes
Blood Cells
Polymerase Chain Reaction
Survival
Therapeutics
Population
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

The role of HER 2/neu in patients with metastatic breast cancer undergoing high-dose chemotherapy. / Bewick, M.; Chadderton, A.; Glück, S.

In: Experimental Hematology, Vol. 24, No. 9, 01.12.1996.

Research output: Contribution to journalArticle

@article{76ea9acde86a4459846107decc04aa71,
title = "The role of HER 2/neu in patients with metastatic breast cancer undergoing high-dose chemotherapy",
abstract = "HER 2/neu is known to be overexpressed in approximately Vb of newly diagnosed breast cancers but has not been examined in the majority of breast cancers that recurred after initial treatment. It was therefore evaluated using two different techniques whether the HER 2/neu product in the plasma (measured by EIA technique) and overexpression of the HER 2/neu oncogene (detected by semiquantative differential PCR) can be used as a prognostic marker, as a too] for detecting minimal residual disease after chemotherapy and also as a marker for treatment outcome. Plasma and peripheral blood samples were analyzed prior to treatment, during chemotherapy and after high-dose chemotherapy. The breast cancer patients were stratified for bone marrow involvement. Our results show a correlation between the amount of HER 2/neu protein product detected in the peripheral blood, the overexpression of the HER 2/neu in the peripheral blood cell population and the involvement of the patient's bone marrow. The study is ongoing and correlation between treatment outcomes and survival of over 32 patients is evaluated.",
author = "M. Bewick and A. Chadderton and S. Gl{\"u}ck",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "24",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - The role of HER 2/neu in patients with metastatic breast cancer undergoing high-dose chemotherapy

AU - Bewick, M.

AU - Chadderton, A.

AU - Glück, S.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - HER 2/neu is known to be overexpressed in approximately Vb of newly diagnosed breast cancers but has not been examined in the majority of breast cancers that recurred after initial treatment. It was therefore evaluated using two different techniques whether the HER 2/neu product in the plasma (measured by EIA technique) and overexpression of the HER 2/neu oncogene (detected by semiquantative differential PCR) can be used as a prognostic marker, as a too] for detecting minimal residual disease after chemotherapy and also as a marker for treatment outcome. Plasma and peripheral blood samples were analyzed prior to treatment, during chemotherapy and after high-dose chemotherapy. The breast cancer patients were stratified for bone marrow involvement. Our results show a correlation between the amount of HER 2/neu protein product detected in the peripheral blood, the overexpression of the HER 2/neu in the peripheral blood cell population and the involvement of the patient's bone marrow. The study is ongoing and correlation between treatment outcomes and survival of over 32 patients is evaluated.

AB - HER 2/neu is known to be overexpressed in approximately Vb of newly diagnosed breast cancers but has not been examined in the majority of breast cancers that recurred after initial treatment. It was therefore evaluated using two different techniques whether the HER 2/neu product in the plasma (measured by EIA technique) and overexpression of the HER 2/neu oncogene (detected by semiquantative differential PCR) can be used as a prognostic marker, as a too] for detecting minimal residual disease after chemotherapy and also as a marker for treatment outcome. Plasma and peripheral blood samples were analyzed prior to treatment, during chemotherapy and after high-dose chemotherapy. The breast cancer patients were stratified for bone marrow involvement. Our results show a correlation between the amount of HER 2/neu protein product detected in the peripheral blood, the overexpression of the HER 2/neu in the peripheral blood cell population and the involvement of the patient's bone marrow. The study is ongoing and correlation between treatment outcomes and survival of over 32 patients is evaluated.

UR - http://www.scopus.com/inward/record.url?scp=33748622278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748622278&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 9

ER -